Cancer cells proliferate, differentiate and migrate by repurposing physiological signalling
mechanisms. In particular, altered calcium signalling is emerging as one of the most …

Abstract Protein arginine methyltransferase 5 (PRMT5) was discovered two decades ago.
The first decade focused on the biochemical characterization of PRMT5 as a regulator of …

Comprehensive genomic studies have delineated key driver mutations linked to disease
progression for most cancers. However, corresponding transcriptional changes remain …

Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that can change the
expression of downstream target genes by catalyzing the trimethylation of lysine 27 of …

ABSTRACT NXPH4 is discovered to be a neuropeptide-like glycoprotein, belonging to the
Neurexophilins (Nxphs) family. NXPH4 shares a similar domain structure with NXPH1 …

Prostate cancer (PCa) is the second most common malignancy among men worldwide.
Although early-stage disease is curable, advanced stage PCa is mostly incurable and …

Enhancer of zeste homolog 2 (EZH2) regulates gene expression and plays a definite role in
cell proliferation, apoptosis, and senescence. Overexpression of EZH2 has been found in …

The use of chemotherapeutic agents and the development of new cancer therapies over the
past few decades has consequently led to the emergence of myriad therapeutic resistance …

Preclinical studies indicate that the epigenome is a potential target in prostate cancer, and
clinical trials are testing multiple agents that target the epigenome in different ways …

Abiraterone acetate has been clinically approved for the treatment of patients with advanced‐
stage prostate cancer. It reduces testosterone production by blocking the enzyme …